Promising Results for Daclizumab High-Yield in MS Medscape October 27, 2011 (Amsterdam, the Netherlands) — Full results of the SELECT trial comparing 2 doses of daclizumab high-yield process (Biogen Iden/Abbott) with placebo confirm that both doses reduced annualized relapse rates by around 50% and had a ... |
